key: cord-0969693-mz4286bl
authors: Liu, Li-Ping; Zhang, Xiao-Li; Li, Jian
title: New perspectives on angiotensin-converting enzyme 2 and its related diseases
date: 2021-06-15
journal: World J Diabetes
DOI: 10.4239/wjd.v12.i6.839
sha: d32643e56d278af8b0f385c3ea4ee7cd9607367b
doc_id: 969693
cord_uid: mz4286bl

Since the worldwide outbreak of coronavirus disease 2019, angiotensin-converting enzyme 2 (ACE2) has received widespread attention as the cell receptor of the severe acute respiratory syndrome coronavirus 2 virus. At the same time, as a key enzyme in the renin-angiotensin-system, ACE2 is considered to be an endogenous negative regulator of vasoconstriction, proliferation, fibrosis, and proinflammation caused by the ACE-angiotensin II-angiotensin type 1 receptor axis. ACE2 is now implicated as being closely connected to diabetes, cardiovascular, kidney, and lung diseases, and so on. This review covers the available information on the host factors regulating ACE2 and discusses its role in a variety of pathophysiological conditions in animal models and humans.

Angiotensin-converting enzyme 2 (ACE2), as the key enzyme in the renin angiotensin system (RAS) and key cell receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has received considerable attention[1] since coronavirus disease 2019 (COVID-19) has spread worldwide. Patients with diabetes and renal and cardiovascular diseases are widely treated with ACE inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), which are deemed to potentially increase ACE2 expression in the body; the consequent increased expression of ACE2 could facilitate infection with SARS-CoV-2. The paradox of the use of ACEI/ARB treatment to interfere with the RAS because ACE2 reduces inflammation (which has been suggested as a therapy for inflammatory lung diseases, diabetes, and hypertension) and the probable contribution of ACE2 to an increased risk of COVID-19 have puzzled clinicians and attracted much attention [2, 3] . Therefore, it is necessary to further understand the characteristics of ACE2 and accurate details of the molecular mechanisms of ACE2 that underlie these phenomena. This review will focus on the biological function of ACE2 and its host regulatory factors. Moreover, we will discuss the role of ACE2 in a variety of pathophysiological conditions, including cardiovascular, kidney, and lung diseases and diabetes in animal models and humans. We aim to provide new perspectives on ACE2 and help us better understand the role of ACE2 in SARS-CoV-2 infection and its treatment nowadays (Figure 1 ).

ACE2 is a type I membrane protein that includes an N-terminal peptidase domain (PD) and a C-terminal collectrin-like domain. The PD of ACE2 provides a direct binding site for the S protein of coronavirus [4] . ACE2 was discovered in 2000 when Tipnis et al [5] and Donoghue et al [6] cloned ACE2 from a human heart failure (HF) cDNA library and a human lymphoma cDNA library and found to be a homolog of the ACE gene. The gene is located in the Xp22 region and has a total length of approximately 39.98 kb, including 18 exons and 17 introns. ACE2 can be hydrolyzed by depolymerase into soluble ACE2, and therefore, ACE2 has two forms, the membranelinked type and the soluble type. Membrane-linked ACE2 is an extracellular enzyme that is distributed on the cell membrane surface and consists of four parts: The Nterminal signal peptide region, the zinc binding motif (amino acid residues 374 to 378), the transmembrane region (amino acids 740 to 768), and the C-terminal intracellular domain. Dissolved ACE2 is distributed mainly in the plasma and urine due to the lack of a transmembrane region and a C-terminal intracellular domain [5] . ACE2 is widely expressed in many organs, including the heart, kidney, testis, adipose tissue, brain tissue, vascular smooth muscle cells, gastrointestinal tract, and lung (type 2 alveolar epithelial cells) and is highly specific in tissues [7] . into angiotensin 1-7 (Ang 1-7), which can lower blood pressure [10] . Increasing evidence demonstrates that ACE2 plays an important role in a variety of pathophysiological conditions. In the tumor microenvironment, ACE2 acts on Ang II to produce endogenous Ang 1-7. Ang 1-7 binds to the Mas receptor (MasR) and exerts antitumor effects such as antiproliferation, antiangiogenesis, anti-invasion, and antimetastasis effects through a series of signal transduction pathways. In diabetes, upregulation of ACE2 can improve hyperglycemia, and Ang 1-7 can improve metabolic syndrome through glucose intake and oxidative stress related to insulin resistance [11] . The expression of ACE2 is related to atherosclerosis [12] . The overexpression of ACE2 can improve endothelial-dependent vascular relaxation, increase the proliferative activity of endothelial cells, and facilitate the migration of endothelial cells. ACE2 exerts anti-infective properties through Ang 1-7[13]. The decrease in aortic ACE2 expression increases the expression of proinflammatory factors, such as tumor necrosis factor α, interleukin-6, monocyte chemotactic protein 1, vascular cell adhesion molecule 1, matrix metalloproteinase (MMP)-2 and MMP-9, which are conducive to the adhesion of leukocytes to endothelial cells and blood vessel walls. In addition, ACE2 can also regulate the adhesion of macrophages to endothelial cells [14] . The combination of Ang 1-7 and MasR can also inhibit the formation of thrombi[15] and liver fibrosis [16] . In ischemic stroke, Ang 1-7 can reduce the area of cerebral infarction and brain dysfunction by regulating the release of nitric oxide from different sources to protect the brain. In addition, Ang 1-7 in brain tissue can regulate learning and memory functions. In the reproductive system, Ang 1-7 can regulate endometrial function, spermatogenesis, follicular maturation, ovulation, and pregnancy-related processes [11] . ACE2 can also regulate the immunity of intestinal epithelial cells through amino acid homeostasis, expression of antimicrobial peptides, and regulation of the balance of intestinal microbes [17] .

HS intake caused an increase in the cortical expression of ACE and a decrease in ACE2, accompanied by increased blood pressure. Elevated blood pressure is associated with a significant increase in Ang II levels in the renal cortex in obese rats and a decrease in the expression of the ACE2-AT2R-MasR axis in obese Zucker rats. In a study of a left nephrectomy rat model [20] , HS diet intake increased the glomerular ACE/ACE2 ratio, which was associated with decreased ACE2. In ACE2 KO mice, ACE2 deficiency significantly increased renal oxidative stress by reducing the production of Ang 1-7. In another study, the consumption of a HS diet in normotensive animals reduced ACE2 protein expression and raised renal oxidative stress [21] . Another study showed that the ACE/ACE2 protein ratio was increased in the kidneys of spontaneously hypertensive rats (SHRs) when fed diets with high levels of NaCl. At the same time, compared to the other SHR groups, there was an increase in kidney ACE2 protein and activity in the group fed a long-term low salt diet [18] . Similarly, Varagic et al [22] used an SHR model to prove that HS intake decreased cardiac ACE2 mRNA and protein expression. In Dahl salt-sensitive hypertensive rats, a HS diet reduced ACE2 mRNA expression and augmented the local RAS, which induced hypertension [23] . The HS diet also decreased ACE2 protein expression as assessed using immunohistochemistry compared to a normal-salt diet [24] .

In summary, these findings show that a HS diet can reduce the expression of ACE2, thereby affecting the RAS. Further studies have reported that interventions that augment ACE2 expression or activity can be helpful to prevent cardiovascular damage [25] . Therefore, elucidating the precise mechanisms involved in the interaction of sodium intake and ACE2 will be conducive to predicting the physiological and pathological changes caused by a HS diet (Table 1) .

Some studies in animal models have demonstrated that both ACEIs (lisinopril, enalapril, and ramipril) and ARBs (losartan, olmesartan, and telmisartan) can upregulate ACE2 expression. Ferrario et al [26] showed that ACE2 mRNA expression increased in the left ventricle of normotensive Lewis rats after 12 d of lisinopril or losartan treatment. Lisinopril increased ACE2 levels by 5-fold, while losartan increased ACE2 levels by 3-fold. A rat study from Ocaranza et al [27] showed that enalapril prevented the decrease in mRNA levels and activities of ACE2 in late ventricular dysfunction after myocardial infarction. The results of Ishiyama et al [28] indicated that the level of ACE2 mRNA increased after ARB treatment in rats with coronary artery ligation. A mouse study by Soler et al [29] showed that ACE2 is preferentially localized in the tunica media of kidney arterioles, and its expression is amplified after administration of telmisartan. On the other hand, some association studies have shown no increase in ACE2 mRNA after ACEI or ARB treatment. An animal study by Burrell et al [30] found that ramipril attenuated cardiac hypertrophy and inhibited cardiac ACE but had no effect on cardiac ACE2 mRNA in rats after coronary artery ligation. Subsequent studies by Burchill et al [31] provided evidence that there was no increase in ACE2 mRNA or protein expression in rats after coronary artery ligation and treatment with valsartan, ramipril, or both when compared to the control group. In general, these studies on experimental animals did not provide consistent evidence to prove the effect of ARB/ACEI administration on ACE2 protein expression. In the case of simulating human drug delivery, further experimental studies are needed.

With the pandemic of COVID-19 spreading since January 2020, it has been inferred that increased ACE2 expression in the lungs correlated with a higher risk of SARS-CoV-2 infection in patients with cardiac and renal diseases, hypertension, and diabetes treated with ACEIs or ARBs. However, a review from Sriram and Insel [32] showed that there was no clear evidence that elevated ACE2 expression when using ACEIs/ARBs could increase the risk of SARS-CoV-2 infection. In a study of 362 hospitalized hypertensive COVID-19 patients, there was no significant difference between severe and noncritical patients or between non-survivors and survivors according to the use of ACEIs and/or ARBs [33] . Conversely, in a recent meta-analysis from Chu et al [34] , it was suggested that ACEI treatment reduced the risk of infection with SARS-CoV-2 and that blocking the RAS might decrease all-cause mortality in COVID-19 patients. This study also reported that ACEIs reduced the risk of non-COVID pneumonia and all-cause mortality caused by non-COVID pneumonia. The effect of ACEIs/ARBs on the expression of ACE2 and the effect on human infection with SARS-CoV-2 remain unknown and complex. Some research has supported the hypothesis 

The functional components of the RAS are in balance with each other to maintain the health of the body. Under certain pathological conditions, Ang II, AT1R, or ACE levels can increase or become unbalanced, which is detrimental. It has been two decades since the discovery of ACE2. During this period, efforts towards the characterization of this enzyme have provided greater insights into the RAS. The ongoing studies provoked more questions, particularly regarding the role of ACE2 in the development and progression of hypertension and renal injury, as well as other pathologies, including diabetes, HF, liver fibrosis, and lung injury (Tables 3 and 4 ).

The kidney possesses a fully functional local RAS capable of producing Ang II, a major contributor to the progression of chronic kidney disease. ACE2 is highly expressed in the kidney and predominantly localized to proximal tubules and glomerular podocytes [39, 40] . Several lines of evidence indicate that ACE2 serves as a key protective enzyme to prevent progressive renal damage by reducing oxidative stress, inflammation, and fibrosis [41] [42] [43] .

The study of ACE2 in the context of diabetes has focused primarily on the kidney. ACE2 may be an important target for the treatment and prevention of diabetic nephropathy (DN). ACE2 expression in the kidney has been studied in both type 1 diabetes (T1D) and type 2 diabetes (T2D) models. The majority of animal studies indicate that ACE2 expression is downregulated in the glomeruli in diabetes, whereas tubular ACE2 expression is upregulated [41, [44] [45] [46] . Tikellis et al [47] first reported that ACE2 expression was reduced in the kidneys of rats with longstanding diabetes . In another rat study, the injection of adenoviral (Ad)-ACE2 in STZ-induced diabetic rats for 4 wk improved many signs of DN [52] . Furthermore, Ad-ACE2 and ACEI had similar effects, whereas the combined use of Ad-ACE2 and ACEI offered no additional benefits [52] .

In humans, the expression of ACE2 was significantly reduced in both the glomeruli and proximal tubules in biopsy samples collected from patients with T2D-induced kidney disease [53] . Conversely, in a real-time polymerase chain reaction study, ACE2 mRNA expression was not significantly changed in eight diabetic patients with overt proteinuria compared with 66 nondiabetic patients with renal disease [54] . The differences in the results obtained in human studies of T2D nephropathy might be due to the different stages of diabetes. To date, no human studies of early-stage diabetes have been conducted. Moreover, genetic variation in and around the gene encoding ACE2 is most often detected using single nucleotide polymorphisms (SNPs). In a recent study, 14 ACE2 polymorphisms were genotyped by matrix-assisted laser desorption ionization time-of-flight mass spectrometry in the Uygur population of the Xinjiang region of China. Among them, the ACE2 SNPs rs2074192, rs4240157, rs4646188, and 879922 were associated with increased microalbuminuria in T2D patients [55] .

Taken together, the above studies suggest that ACE2 might play a protective role against the development of DN.

The role of ACE2 has been intensively studied in models of hypertension. Crackower et al [56] first reported that ACE2 transgenic mice exhibited lower blood pressure than wild-type mice. Subsequent studies reported that ACE2 probably has a small effect on blood pressure in mice under normal conditions[57-59]. However, it plays a much more prominent role in the regulation of hypertension, especially when Ang II levels are elevated. Existing studies have shown that ACE2 was reduced in kidneys from rat models of hypertension, such as salt-sensitive Sabra hypertensive rats, SHRs, and stroke-prone SHRs (SHRSP) [56, 60] . Moreover, in a sheep model of fetal programmed hypertension, the administration of betamethasone on the 80 th day of gestation markedly reduced ACE2 activity in the proximal tubules and urine in adolescent sheep [61] . Rentzsch et al [62] assessed the role of ACE2 in the pathogenesis of Transgenic rats Transgenic rats were generated in an SHRSP genetic background expressing human ACE2 in vascular smooth muscle cells by the use of the SM22 promoter (SHRSP-ACE2 model)

Mean arterial blood pressure was reduced in SHRSP-ACE2, and the vasoconstrictive response to intraarterial administration of angiotensin II was attenuated Rentzsch et al [62] SHR Male WKY rats were randomized to receive either placebo or rhACE2 and were subsequently infused with Ang II Treatment with rhACE2 partly corrected the hypertension, NADPH oxidase activation, and increased superoxide generation in the heart, kidney, and blood vessels Lo et al [63] Mice ACE2 activity was measured in kidney cortex from mice that had received injection of MLN-4760 or DX600

A marked increase in serum ACE2 activity. Mouse ACE2 abolished the hypertension induced by Ang II infusion. These effects were blocked by MLN-4760 but not by DX600

Ye et al [64] ACE2-deficient mice ACE2 mutant mice were generated, and heart parameters were measured Genetic inactivation of ACE2 using homologous recombination resulted in increased AngII peptide levels, upregulation of hypoxia genes in the heart, and severe cardiac dysfunction hypertension. These authors generated transgenic rats in a SHRSP genetic background, called SHRSP-ACE2, which expressed human ACE2 in vascular smooth muscle cells under the control of the smooth muscle 22α promoter. They found that endothelial function was significantly improved in SHRSP-ACE2 rats compared with SHRSP rats. These data indicate that vascular ACE2 overexpression in SHRSP reduces hypertension, probably through local Ang II degradation and by improving endothelial function. Existing animal studies have shown that the administration of recombinant ACE2 (rACE2) degrades Ang II, lowers blood pressure, and attenuates Ang II-induced T2D: type 2 diabetes; EH: Essential hypertension; ACE2: Angiotensin-converting enzyme 2; ARDS: Acute respiratory distress syndrome; SNP: Single nucleotide polymorphism; HF: Heart failure; HFrEF: Heart failure and reduced ejection fraction; HFpEF: Heart failure and preserved ejection fraction; Ang 1-7: Angiotensin 1-7.

organ injury. One study showed that in the SHR model, rhACE2 partly corrected hypertension and NADPH oxidase activation and increased superoxide generation in the heart, kidney, and blood vessels over a 14-d period [63] . Moreover, the prevention of Ang II-induced hypertension by mouse rACE2 was completely abolished by the specific ACE2 inhibitor MLN-4760, a nonpeptide inhibitor no longer available from Millennium Pharmaceuticals [64] . In human studies, Patel et al [65] found that in Caucasians with T2D, genetic variation in ACE2 is associated with hypertension and reduced systolic function in men and hypertension and increased left ventricular mass in women. Liu et al [55] found that the ACE2 SNPs rs2048683, rs233575, rs4240157, rs4646156, rs4646188, and rs879922 were associated with increased systolic blood pressure (SBP), while rs2074192, rs4646188, and rs879922 were associated with elevated diastolic blood pressure in Uygur T2D patients. Luo et al [66] revealed that the ACE2 variant rs2074192 was associated with essential hypertension (EH), while three ACE2 variants (rs4240157, rs4646155, and rs4830542) were associated with EH-and hypertensionrelated atrial fibrillation and left atrial remodeling in south Xinjiang, China. In another study, the ACE2 rs2106809 T allele was found to confer a 1.6-fold risk for hypertension in women [67] . Additionally, one study showed that aberrant methylation of the ACE2 promoter may be associated with EH risk [68] .

These findings indicate that ACE2 is a key regulator that maintains the balance of blood pressure. In animal studies, it has been demonstrated that the administration of recombinant ACE2 has a beneficial effect on the treatment of hypertension. Currently, large clinical trials to explore this and related alternative interventions are underway.

SARS-CoV-2 enters the upper respiratory epithelium and lungs predominantly through ACE2. Nevertheless, in a single-center report of 416 patients hospitalized with COVID-19, 19.7% showed evidence of cardiac injury, suggesting a possible pathologic role for myocardial ACE2 expression [69] . ACE2 is present on endothelial cells and can undergo so-called shedding into the circulation. In patients with cardiovascular disease, increased ACE2 activity in the circulation predicts adverse cardiovascular outcomes in patients with HF, coronary artery disease, and aortic stenosis [70] . Crackower et al[56] demonstrated the first evidence that ACE2 may have a role in cardiac function. They found that ACE2 deletion in mice resulted in a severe heart contractility defect, increased levels of Ang II in the kidney, heart, and plasma, and upregulation of hypoxia-induced genes in the heart. Conversely, Gurley et al [57] reported that ACE2 deletion enhanced susceptibility to Ang II-induced hypertension but had no effect on cardiac structure or function. Huentelman et al [71] showed that ACE2 overexpression protects the heart from Ang II-induced hypertrophy and fibrosis. Another study on SHR hypertensive rats also showed that ACE2 overexpression exerted protective effects against high blood pressure and cardiac pathophysiology induced by hypertension [72] . Similarly, in a rabbit atherosclerosis model, local overexpression of ACE2 significantly inhibited the development of early atherosclerotic lesions [73] .

In humans, increased circulating ACE2 activity is associated with coronary heart disease and HF, and a large proportion of the variation in plasma ACE2 levels is attributed to hereditary factors. One study showed that ACE2 activity was significantly increased in HF patients with reduced ejection fraction (HFrEF). Serum ACE2 activity was negatively correlated with left ventricular systolic function in HfrEF [74] . In addition, one study measured soluble ACE2 (sACE2) activity in 113 patients with chronic systolic HF and showed that elevated plasma sACE2 activity was associated with greater severity of myocardial dysfunction, which indicated that plasma sACE2 activity might be an independent predictor of adverse clinical events [75] . A recent study published in Lancet presented one of the largest epidemiological datasets on plasma ACE2 concentration in the general population [76] . They performed a casecohort study involving 10753 participants from the multinational Prospective Urban Rural Epidemiology study, including 5084 patients randomly selected as the subcohort and 5669 with an incident event of interest. They reported that ACE2 concentration was the highest-ranked independent predictor of death compared with standard cardiovascular risk markers (smoking, diabetes, SBP, non-high density lipoprotein cholesterol, and body mass index). An increased concentration of plasma ACE2 was associated with an increased risk of all-cause mortality [hazard ratio (HR): 1.35 per 1 standard deviation (SD) increase; 95% confidence interval (CI): 1.29-1.43], incident HF (HR: 1.27 per 1 SD increase; 95%CI: 1.10-1.46), stroke (HR: 1.21 per 1 SD increase; 95%CI: 1.10-1.32), myocardial infarction (HR: 1.23 per 1 SD increase; 95%CI: 1.13-1.33), and incident diabetes (HR: 1.44 per 1 SD increase; 95%CI: 1.36-1.52). Other studies have investigated whether the ACE2 gene is associated with left ventricular hypertrophy and coronary artery disease. The ACE2 SNPs most frequently used in association studies are rs2285666 and rs1978124 [77] . Recently, Liu et al [55] found that the ACE2 SNPs rs2074192 and rs879922 were associated with carotid arteriosclerosis stenosis and that the ACE2 SNPs rs2048683, rs4240157, rs4646156, rs4646188, and rs879922 were linked to more substantial left heart remodeling. Furthermore, one study assessed ACE2 expression by performing bulk and single nucleus RNA-Seq on the left ventricles of 11 individuals with dilated cardiomyopathy, 15 individuals with hypertrophic cardiomyopathy, and 16 controls with nonfailing hearts from the Penn Human Heart Tissue Biobank. They found that cardiac ACE2 expression was downregulated in fibroblasts, pericytes, and vascular smooth muscle but upregulated in cardiomyocytes [69] .

Investigations of ACE2 as well as its role in cardiac function and HF will undoubtedly provide greater insight into the roles of this enzyme. However, carefully conducted large-scale clinical studies are urgently needed to clarify the potential role of ACE2 in cardiovascular diseases more precisely.

Like many other organ lung cells also have a local RAS [78] , which influences the pathogenesis of lung injury via cellular effects, including changes in vascular permeability, vascular tone, fibroblast activity, or alveolar epithelial cell apoptosis [79, 80] . ACE2 plays a pivotal role in Ang II degradation in the RAS cascade and thus limits inflammation and fibrosis in the lung[81]. Imai et al [82] investigated the role of ACE2 in acute respiratory distress syndrome (ARDS) by using ACE2 knockout mice. In three different ARDS models (acid-aspiration-induced, endotoxin-induced, and peritoneal sepsis-induced ARDS), it was shown that a loss of ACE2 expression in mutant mice resulted in enhanced vascular permeability, increased lung edema, engendered neutrophil accumulation, and worsened lung function. Importantly, treatment with catalytically active recombinant ACE2 protein improved the symptoms of acute lung injury in both wild-type mice and ACE2 knockout mice. Thus, ACE2 plays a protective role in acute lung injury. Mechanically, the finding that reduced ACE2 on lung cell surfaces is correlated with lung damage due to an uncontrolled RAS cascade is supported by data about the effects of long-lasting hyperoxia on pulmonary tissue [82] [83] [84] [85] [86] . In addition, a study revealed that ACE2 activation can reduce the severity of lipopolysaccharide-induced acute lung injury via the activated serine/threonine protein kinase/mammalian target of rapamycin pathway [87] .

In the current pandemic of COVID-19, both bioinformatics modeling and in vitro experiments indicate that SARS-CoV-2 likely utilizes ACE2 as a receptor to gain entry into human cells [88] [89] [90] . A recent study evaluated lung function in a mouse model of SARS-CoV-2 infection. They used transgenic mice expressing the human ACE2 (hACE2) receptor driven by the cytokeratin-18 (K18) gene promoter (K18-hACE2) and found that intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice resulted in high levels of viral infection in the lungs, with spread to other organs [91] . Similarly, one study also used a model of mice expressing hACE2 in the lung. In this study, the mice were transduced by oropharyngeal delivery of recombinant human adenovirus type 5 expressing hACE2 [92] . They found that mice were infected with SARS-CoV-2 at day 4 post-transduction and developed interstitial pneumonia related to perivascular inflammation. On the other hand, as described above, a similar decrease in ACE2 has also been seen in cases of COVID-19 with severe lung injury, which might be attributable to the negative consequences that arise from insufficient Ang II degradation [93] . In human trials, GSK2586881, a rhACE2, was well tolerated in 44 patients with ARDS and has been found to reduce Ang II levels and increase Ang 1-7 levels, although it failed to improve the physiological and clinical indicators of ARDS in patients [94] . This study likely represents the first clinical application of rhACE2 in the field of ARDS, so we speculate that rhACE2 may become one of the most promising approaches for protecting against lung injury in patients with COVID-19.

Based on the above description, ACE2 plays a complex role in COVID-19-induced acute lung injury. On the one hand, high levels of ACE2 receptors on the cell surface may accelerate the invasion of SARS-CoV-2 during the very early phase of infection. On the other hand, low levels of ACE2 can ultimately worsen the disease course due to insufficient Ang II conversion in cases of severe COVID-19 with pulmonary complications.

As a vital component of the RAS, ACE2 is closely related to the occurrence and development of RAS-associated diseases. A better understanding of the biological functions of ACE2 will be beneficial to the treatment. Previous studies show that a high-salt diet can decrease the expression of ACE2 and cause RAS disorders. Recent reports have not yet indicated that ARBs or ACEIs will increase the level of ACE2, thereby aggravating SARS-CoV-2 infection. Therefore, the mechanisms involved need to be further improved. As ACE2 is an important receptor through which SARS-CoV-2 can invade cells, further studies on ACE2 should focus on the development of drugs that inhibit the virus from entering cells and impede the binding of the S protein to ACE2 for COVID-19 treatment. More research on ACE2 should be conducted in the future to carry out targeted and effective treatment at a higher level.

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Drugs, COVID-19' working group of the French Society of Pharmacology, Therapeutics. Renin-angiotensin-aldosterone system and COVID-19 infection

Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function

ACE and ACE2 in kidney disease

ACE2 and diabetes: ACE of ACEs?

The sweeter side of ACE2: physiological evidence for a role in diabetes

Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits

Diminazene aceturate prevents nephropathy by increasing glomerular ACE2 and AT 2 receptor expression in a rat model of type1 diabetes

Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes

Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy

Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination

Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury

ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes

Human recombinant ACE2 reduces the progression of diabetic nephropathy

Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease

Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy

ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice

Does ACE2 contribute to the development of hypertension?

Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II

Developmental expression of ACE2 in the SHR kidney: a role in hypertension?

Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension

Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function

Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats

Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin IIdependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2

Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes

Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south Xinjiang

Study Group for Pharmacogenomic Based Antihypertensive Drugs Selection, Effects and Side Effects, in Rural Area Chinese. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women

Preliminary analysis of the association between methylation of the ACE2 promoter and essential hypertension

Ellinor PT; Human Cell Atlas Lung Biological Network Consortium Members. Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2-Mediated Myocarditis

Circulating ACE2: a novel biomarker of cardiovascular risk

Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats

ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR

Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells

Circulating ACE2 activity correlates with cardiovascular disease development

Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes

Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis

angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications

the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis

Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases

The renin-angiotensin system in pulmonary hypertension

Renin-angiotensin system and its role in hyperoxic acute lung injury

Angiotensin-converting enzyme 2 protects from severe acute lung failure

The renin-angiotensin system -a therapeutic target in COVID-19

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Prior hypoxia prevents downregulation of ACE-2 by hyperoxia in fetal human lung fibroblasts

The conundrum of using hyperoxia in COVID-19 treatment strategies: may intermittent therapeutic hyperoxia play a helpful role in the expression of the surface receptors ACE2 and Furin in lung tissue via triggering of HIF-1α?

Angiotensin-converting enzyme 2 regulates autophagy in acute lung injury through AMPK/mTOR signaling

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19

Bioinformatic analysis of SMN1-ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Lung Expression of Human Angiotensin-Converting Enzyme 2 Sensitizes the Mouse to SARS-CoV-2 Infection

Two hits to the renin-angiotensin system may play a key role in severe COVID-19

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

It has been widely demonstrated that a high-sodium (HS) diet activates the RAS. Animal experiments have proven that salt intake is a powerful regulator of ACE2 expression in animal models [18]. Studies by Samuel et al [19] found that the relative expression patterns of ACE and AT1R increased, renin levels decreased, and ACE2, AT2R, and MasR remained unaltered in HS-fed lean Zucker rats. On the other hand,